JP2010529173A - 神経活性の測定 - Google Patents

神経活性の測定 Download PDF

Info

Publication number
JP2010529173A
JP2010529173A JP2010511649A JP2010511649A JP2010529173A JP 2010529173 A JP2010529173 A JP 2010529173A JP 2010511649 A JP2010511649 A JP 2010511649A JP 2010511649 A JP2010511649 A JP 2010511649A JP 2010529173 A JP2010529173 A JP 2010529173A
Authority
JP
Japan
Prior art keywords
alkyl
hydrogen
labeled compound
labeled
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010511649A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010529173A5 (US20100247435A1-20100930-C00020.png
Inventor
アースタッド，エリック
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hammersmith Imanet Ltd
Original Assignee
Hammersmith Imanet Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hammersmith Imanet Ltd filed Critical Hammersmith Imanet Ltd
Publication of JP2010529173A publication Critical patent/JP2010529173A/ja
Publication of JP2010529173A5 publication Critical patent/JP2010529173A5/ja
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/534—Production of labelled immunochemicals with radioactive label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2842—Pain, e.g. neuropathic pain, psychogenic pain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2857—Seizure disorders; Epilepsy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/302—Schizophrenia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/28—Details of apparatus provided for in groups G01R33/44 - G01R33/64
    • G01R33/281—Means for the use of in vitro contrast agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/48—NMR imaging systems
    • G01R33/54—Signal processing systems, e.g. using pulse sequences ; Generation or control of pulse sequences; Operator console
    • G01R33/56—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution
    • G01R33/5601—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution involving use of a contrast agent for contrast manipulation, e.g. a paramagnetic, super-paramagnetic, ferromagnetic or hyperpolarised contrast agent
JP2010511649A 2007-06-14 2008-06-12 神経活性の測定 Pending JP2010529173A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94387207P 2007-06-14 2007-06-14
PCT/EP2008/057418 WO2008152109A1 (en) 2007-06-14 2008-06-12 Measurement of neural activity

Publications (2)

Publication Number Publication Date
JP2010529173A true JP2010529173A (ja) 2010-08-26
JP2010529173A5 JP2010529173A5 (US20100247435A1-20100930-C00020.png) 2012-07-12

Family

ID=39689029

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010511649A Pending JP2010529173A (ja) 2007-06-14 2008-06-12 神経活性の測定

Country Status (5)

Country Link
US (1) US20100247435A1 (US20100247435A1-20100930-C00020.png)
EP (1) EP2155260A1 (US20100247435A1-20100930-C00020.png)
JP (1) JP2010529173A (US20100247435A1-20100930-C00020.png)
CN (1) CN101678127A (US20100247435A1-20100930-C00020.png)
WO (1) WO2008152109A1 (US20100247435A1-20100930-C00020.png)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010215572A (ja) * 2009-03-17 2010-09-30 Japan Health Science Foundation 歯髄炎診断マーカー及び歯髄炎診断システム
GB201203793D0 (en) 2012-03-05 2012-04-18 Ge Healthcare Ltd Imaging neural activity
US10390727B2 (en) 2017-04-21 2019-08-27 The Charles Stark Draper Laboratory, Inc. Apparatus and method for imaging currents using nanoparticles and low-field magnetic resonance imaging (MRI)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002509860A (ja) * 1998-01-29 2002-04-02 エール ユニヴァーシティ 後根神経節におけるナトリウムチャンネルの調節

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5303705A (en) * 1992-05-01 1994-04-19 Nenov Valeriy I Evoked 23NA MR imaging of sodium currents in the brain
NZ296748A (en) * 1994-11-02 1999-11-29 Univ New York State Res Found Peripheral nervous system specific sodium channel proteins, DNA coding therefor, compositions and methods
BR0009322A (pt) * 1999-03-26 2002-04-30 Euro Celtique Sa Pirazóis, imidazóis, oxazóis, tiazóis e pirróis substituìdos com arila e o uso dos mesmos
AR056317A1 (es) * 2005-04-20 2007-10-03 Xenon Pharmaceuticals Inc Compuestos de oxindol y composicion farmaceutica

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002509860A (ja) * 1998-01-29 2002-04-02 エール ユニヴァーシティ 後根神経節におけるナトリウムチャンネルの調節

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN6013008176; Ｊ．ＭＥＤ．ＣＨＥＭ． ＶＯＬ．４７, 2004, Ｐ．１５４７-１５５２ *
JPN6013008177; Ｊ．ＭＥＤ．ＣＨＥＭ． ＶＯＬ．４７, 2004, Ｐ．４２７７-４２８５ *
JPN6013008178; ＢＩＯＯＲＧＡＮＩＣ　＆　ＭＥＤＩＣＩＮＡＬ　ＣＨＥＭＩＳＴＲＹ　ＬＥＴＴＥＲＳ ＶＯＬ．１４, 2004, Ｐ．３５２１-３５２３ *

Also Published As

Publication number Publication date
WO2008152109A1 (en) 2008-12-18
US20100247435A1 (en) 2010-09-30
CN101678127A (zh) 2010-03-24
EP2155260A1 (en) 2010-02-24

Similar Documents

Publication Publication Date Title
Mason et al. Multimodality imaging of hypoxia in preclinical settings
ES2451642T3 (es) Derivados de indol tetracíclicos como agentes de formación de imágenes in vivo y que tienen afinidad por receptores de benzodiazepina periféricos (PBR)
US20110236307A1 (en) In vivo imaging method
EP2305316A2 (en) Diphosphorylated glycopeptide imaging agent for fibrosis
BRPI1006246A2 (pt) "kit para imagem médica marcada e/ou terapias, sonda efetora e método"
WO2010048144A2 (en) Imaging and radiotherapy methods
JP2009518373A (ja) 線維症用の新規造影剤
JP2013514326A (ja) 標識インテグリン結合剤
EP2198040B1 (en) In vivo imaging of myelin
US20090317328A1 (en) Tricyclic oxazepines as in vivo imaging compounds
JP2010529173A (ja) 神経活性の測定
JP2008509921A (ja) 内皮特異的な生体内伝達のターゲティング剤としての熱ショックタンパク質
US20120034165A1 (en) Imaging the central nervous system with purinergic p2x7 receptor binding agents
JP2000344685A (ja) アズールａ類似化合物によるアミロイドが蓄積する疾患の画像診断プローブおよびそれを含む画像診断用組成物
WO2014122228A1 (en) Labelled compounds that bind to alpha-v-beta-3 integrin
CN102307858B (zh) 胰岛成像用分子探针前体及其使用
Sóvágó et al. Lack of effect of reserpine-induced dopamine depletion on the binding of the dopamine-D3 selective radioligand,[11C] RGH-1756
CN101970017B (zh) 中枢神经系统的显像
US20080279771A1 (en) Novel Imaging Agents for Cancer
US11844846B2 (en) Styrylbenzothiazole derivatives and uses in imaging methods
KR20110031320A (ko) 치료의 모니터링
Chang Dopamine D2 Receptor Radiopharmaceutical: I-123-Epidepride Toxicology and Preclinical SPECT Image
JP5128293B2 (ja) 橋頭標識化合物およびその使用方法
JP2016513083A (ja) 放射標識された化合物
EP2377852A1 (en) Labelled huprine derivatives and their use in medical imaging

Legal Events

Date Code Title Description
A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110523

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110523

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120522

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130226

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130723